-
Mashup Score: 4
Results of the EMPERIAL-Reduced and -Preserved trials show benefits related to congestion, however.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 25Heart Failure 2020 Cancellation FAQs - 4 year(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Dear #CardioTwitter, #HeartFailure2020, scheduled for 23–26 May in Barcelona, is officially cancelled https://t.co/zT5qHi4Huy #COVID19 #HFA_ESC #HeartFailure #conferencecancelled
-
-
Mashup Score: 3
Results of the EMPERIAL-Reduced and -Preserved trials show benefits related to congestion, however.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In EMPERIAL-Reduced trial #SGLT2 inhibitor empagliflozin showed favorable effects on diuretic use and congestion symptoms in HF with HFrEF. https://t.co/C89vA5frFm #heartfailure2020 https://t.co/UNd9tvc5Ds
-
-
Mashup Score: 2
Results of the EMPERIAL-Reduced and -Preserved trials show benefits related to congestion, however.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In EMPERIAL-Reduced trial #SGLT2 inhibitor empagliflozin showed favorable effects on diuretic use and congestion symptoms in HF with HFrEF. https://t.co/TEVmxNnK4j #heartfailure2020 https://t.co/krSsxM1bNR
-
-
Mashup Score: 0
Results of the EMPERIAL-Reduced and -Preserved trials show benefits related to congestion, however.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
In EMPERIAL-Reduced trial SGLT2 inhibitor empagliflozin showed favorable effects on diuretic use and congestion symptoms in HF with HFrEF. https://t.co/kHCqmVrXHA #heartfailure2020 https://t.co/bloL8kvUMg
-
-
Mashup Score: 1
Results of the EMPERIAL-Reduced and -Preserved trials show benefits related to congestion, however.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In EMPERIAL-Reduced trial #SGLT2 inhibitor empagliflozin showed favorable effects on diuretic use and congestion symptoms in HF with HFrEF. https://t.co/nItXZkvKOk #heartfailure2020 https://t.co/xMts42IADI
-
-
Mashup Score: 2
Results of the EMPERIAL-Reduced and -Preserved trials show benefits related to congestion, however.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In EMPERIAL-Reduced trial SGLT2 inhibitor empagliflozin showed favorable effects on diuretic use and congestion symptoms in HF with HFrEF. https://t.co/thSMmF9rsn #heartfailure2020 https://t.co/MP11UkUpSf
-
-
Mashup Score: 0Vericiguat Success in HFrEF May Not Apply to Sickest: VICTORIA - 4 year(s) ago
Natriuretic peptide levels may have forecast who would benefit on the novel agent vs who might be more appropriate for ‘nonpharmacological treatment or palliative care,’ said an expert observer.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
VICTORIA trial: Vericiguat success in HFrEF may not apply to sickest. https://t.co/QniVVAC5su #Heartfailure2020
-
-
Mashup Score: 1Fewer Outpatient HF Med Adjustments on Dapagliflozin: DAPA-HF - 4 year(s) ago
The scope of sodium-glucose cotransporter 2 (SGLT2) inhibition’s clinical benefits in DAPA-HF may be greater than already appreciated, suggests a prespecified secondary analysis of the heart failure with reduced ejection fraction (HFrEF) trial. DAPA-HF is already renowned for showing a highly significant 26% drop in clinical events (P < .001) in HFrEF patients who received...
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
New analysis of DAPA-HF adds outpatient intensification of HF therapy to the trial's composite primary end point of CV death, HF hospitalization, and urgent HF visit. https://t.co/2HkPOonqxk #Heartfailure2020
-
-
Mashup Score: 1Women Thrive on Baroreflex Activation for Heart Failure - 4 year(s) ago
The results of the BeAT-HF trial led to marketing approval of the BaroStim Neo system for improvement in symptoms of heart failure with reduced ejection fraction (HFrEF) by the FDA last August.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Results of the BeAT-HF trial. https://t.co/SCj8XXCwLu #heartfailure2020
-
In EMPERIAL-Reduced trial #SGLT2 inhibitor empagliflozin showed favorable effects on diuretic use and congestion symptoms in HF with HFrEF. https://t.co/z6UJJ1AtLn #heartfailure2020 https://t.co/R8oIq0lWmB